Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

F, Tubach; D, Salmon; P, Ravaud; Y, Allanore; P, Goupille; M, Bréban; B, Pallot-Prades; S, Pouplin; A, Sacchi; RM, Chichemanian; S, Bretagne; D, Emilie; M, Lemann; O, Lortholary; X, Mariette

doi:10.1002/art.24632

Public

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Shared by NobleBlocks on Jul 1, 2009 • 12:00 AM UTC

Authors:

Tubach F

Salmon D

Ravaud P

Abstract

Objective Tuberculosis (TB) is associated with anti-tumor necrosis factor (anti-TNF) monoclonal antibody (mAb) therapy, but whether this association is drug-specific remains a concern. Our objective was to describe cases of TB associated with anti-TNF mAb therapy, identify risk factors, and estimate...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!